Skip to main content

Table 4 Prevalence of Pfk13 and Pfmdr1 polymorphisms in day 0 samples (all samples and only those that were reinfected) and day of failure samples (recurrent infections), Ethiopia, 2017

From: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia

Polymorphism

Background Prevalence (all D0 samples)

N = 48

Reinfection (D0)

N = 2

Reinfection (DF)

N = 2

 

N

Percent (%)

n

Percent (%)

n

Percent (%)

Pfk13

 Samples sequenced

48

100

2

100

2

100

 Wild type (no mutations detected)

48

100

2

100

2

100

Pfmdr1†

 N86

47

98

2

100

2

100

 86Y

1

2

0

0

0

0

 Y184

11

23

0

0

0

0

 184Y/F

2

4

0

0

0

0

 184F

35

73

2

100

2

100

 S1034

48

100

2

100

2

100

 1034C

0

0

0

0

0

0

 D1246

48

100

2

100

2

100

 1246Y

0

0

0

0

0

0

Samples sequenced for haplotype analysis

 NYD

13

27

0

0

0

0

 YFD

1

2

0

0

0

0

 NFD

36

75

2

100

2

100

 NFY

0

0

0

0

0

0

 NYY

0

0

0

0

0

0

 YYD

0

0

0

0

0

0

 YFY

0

0

0

0

0

0

 YYY

0

0

0

0

0

0

  1. D0 day zero, DF day of failure; Bold letter denotes an encoded amino acid change; No mutations found at Pfmdr1 codon 1042 and 1246;
  2. †Totals may not sum due to mixed infections